Media Room Menu
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Apr 27, 2020- Libtayo decreased the risk of death by 32.4% compared to chemotherapy
-
Apr 27, 2020• Independent Data Monitoring Committee recommended continuing ongoing Phase 3 trial only in the more advanced “critical” group with Kevzara higher-dose versus placebo and discontinuing less advanced “severe” group
-
Apr 24, 2020Latest innovation in quadrivalent meningococcal vaccination designed for use in persons 2 years of age and older in the U.S.
